Six-month landmark analysis for OS
| Immune variable* . | n . | HR (95% CI) . | P . |
|---|---|---|---|
| ALC | 92 | 0.20 (0.07-0.54)† | .003 |
| CD3+ T cells | 93 | 0.34 (0.19-0.61)† | .001 |
| CD4+ T cells | 93 | 0.30 (0.16-0.56)† | <.001 |
| CD4+CD45RA+ T cells | 93 | 0.90 (0.59-1.39) | .651 |
| CD8+ T cells | 93 | 0.74 (0.45-1.21) | .221 |
| NK cells | 93 | 0.85 (0.31-2.34) | .757 |
| B cells | 93 | 0.80 (0.64-0.99) | .054 |
| PHA | 89 | 0.34 (0.17-0.68)† | .004 |
| Immune variable* . | n . | HR (95% CI) . | P . |
|---|---|---|---|
| ALC | 92 | 0.20 (0.07-0.54)† | .003 |
| CD3+ T cells | 93 | 0.34 (0.19-0.61)† | .001 |
| CD4+ T cells | 93 | 0.30 (0.16-0.56)† | <.001 |
| CD4+CD45RA+ T cells | 93 | 0.90 (0.59-1.39) | .651 |
| CD8+ T cells | 93 | 0.74 (0.45-1.21) | .221 |
| NK cells | 93 | 0.85 (0.31-2.34) | .757 |
| B cells | 93 | 0.80 (0.64-0.99) | .054 |
| PHA | 89 | 0.34 (0.17-0.68)† | .004 |
P values significant at the .01 level are indicated in bold.
In univariable analysis of patient, graft, and posttransplant variables, only recipient age was associated with OS, although not at the 0.01 significance level (HR, 1.78 [95% CI, 1.04-3.03] per decade, P = .025). Patient sex, diagnosis, CMV seropositivity, engrafting CB unit–recipient HLA-match, engrafting CB unit infused viable CD34+ and CD3+ cell doses, addition of haploidentical CD34+ cells, and day 100 aGVHD grade were not significant.
HR adjusted for age.